European Union

EPO Patent Application EP2026030528A1 for Activated Hepatocyte Growth Factor

The European Patent Office (EPO) has published patent application EP2026030528A1 concerning activated hepatocyte growth factor. The publication date is March 18, 2026, and the inventors have not yet been designated.

EPO Patent Application: Cardiomyocyte Delivery Platforms

The European Patent Office has published patent application EP2026030210A1 concerning cardiomyocyte delivery platforms and methods of use. The application was published on March 18, 2026, and lists various IPC classifications related to pharmaceutical compositions and biotechnology.

EPO Patent Publication EP2026029176A1: Anti-Integrin α8β1 Antibody

The European Patent Office (EPO) has published patent application EP2026029176A1 concerning an anti-integrin α8β1 antibody. The publication date is March 18, 2026, and the inventors have not yet been designated.

EPO Patent Application: GLP1 Receptor Ligands for Cardiomyocyte Delivery

The European Patent Office has published a patent application (EP2026030212A1) detailing GLP1 receptor ligands for delivering therapeutic agents to cardiomyocytes. The application was published on March 18, 2026, and lists various IPC classifications related to chemical compounds and medical applications.

EPO Patent Publication: Urea or Carbamate Lipid Nanoparticles

The European Patent Office (EPO) has published a patent application (EP2026029046A1) concerning urea or carbamate lipids with cyclic groups in the side chain, and related lipid nanoparticles and pharmaceutical compositions. The publication date is March 18, 2026.

Klotho mRNA Patent EP4711452A2 Published

The European Patent Office published patent application EP4711452A2 on March 18, 2026, related to Klotho messenger-RNA (mRNA) technology. The patent application was filed by ADvantage Therapeutics, Inc. and details specific compositions and sequences for Klotho polypeptides.

Pandemic Influenza Vaccine Patent Application EP2026029847A1

The European Patent Office has published patent application EP2026029847A1 concerning methods and compositions for a pandemic influenza vaccine. The publication date is March 18, 2026, and the inventors have not yet been designated.

EPO Patent: Wheat Stripe Rust Resistance Genes

The European Patent Office (EPO) has published a limitation for patent EP3370509C0 concerning wheat stripe rust resistance genes and methods of use. The patent, listing Matthew James Moscou and Andrew Marc Dawson as inventors, is set to be limited on March 18, 2026.

EPO Patent Grant EP3455352B1 for Variant Polypeptides

The European Patent Office has granted patent EP3455352B1 for variant polypeptides with improved performance. The patent, which lists Carsten Andersen as an inventor, was published on March 18, 2026, and covers applications in various designated states across Europe.

EPO Patent EP3265098B1: Modulating Mecp2 Expression Compositions

The European Patent Office has granted patent EP3265098B1 for compositions intended to modulate Mecp2 expression. This patent, effective March 18, 2026, covers specific inventions related to biotechnology and pharmaceutical applications.